Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Miriam Rosás-Umbert"'
Autor:
Miriam Rosás-Umbert, Jesper D. Gunst, Marie H. Pahus, Rikke Olesen, Mariane Schleimann, Paul W. Denton, Victor Ramos, Adam Ward, Natalie N. Kinloch, Dennis C. Copertino, Tuixent Escribà, Anuska Llano, Zabrina L. Brumme, R. Brad Jones, Beatriz Mothe, Christian Brander, Julie Fox, Michel C. Nussenzweig, Sarah Fidler, Marina Caskey, Martin Tolstrup, Ole S. Søgaard
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Broadly neutralising anti-HIV-1 antibody (bNAb) administration in nonhuman primates has been shown to stimulate adaptive T cell-specific immunity, with infection prevention observed. In this work, the authors longitudinally analyse HIV-1 specific cel
Externí odkaz:
https://doaj.org/article/ef639b4a891643dcb296cca780fd13c0
Autor:
Beatriz Mothe, Miriam Rosás-Umbert, Pep Coll, Christian Manzardo, Maria C. Puertas, Sara Morón-López, Anuska Llano, Cristina Miranda, Samandhy Cedeño, Miriam López, Yovaninna Alarcón-Soto, Guadalupe Gómez Melis, Klaus Langohr, Ana M. Barriocanal, Jessica Toro, Irene Ruiz, Cristina Rovira, Antonio Carrillo, Michael Meulbroek, Alison Crook, Edmund G. Wee, Jose M. Miró, Bonaventura Clotet, Marta Valle, Javier Martinez-Picado, Tomáš Hanke, Christian Brander, José Moltó, The BCN02 Study Investigators
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label,
Externí odkaz:
https://doaj.org/article/488e5500178f4b47bb1f5b03a865f708
Autor:
Miriam Rosás-Umbert, Marta Ruiz-Riol, Marco A. Fernández, Marta Marszalek, Pep Coll, Christian Manzardo, Samandhy Cedeño, José M. Miró, Bonaventura Clotet, Tomáš Hanke, José Moltó, Beatriz Mothe, Christian Brander, the BCN02 study group, Susana Benet, Anuksa Llano, Javier Martinez-Picado, Sara Morón-López, Roger Paredes, Maria C. Puertas, Roser Escrig, Silvia Gel, Miriam López, Cristina Miranda, Jose Muñoz, Nuria Perez-Alvarez, Jordi Puig, Boris Revollo, Jessica Toro, Ana Maria Barriocanal, Magi Farré, Cristina Perez-Reche, Marta Valle, Juan Ambrosioni, Irene Ruiz, Cristina Rovira, Carmen Ligero, Jose M. Miro, Antonio Carrillo, Michael Meulbroek, Ferran Pujol, Jorge Saz, Nicola Borthwick, Alison Crook, Edmund G. Wee
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T
Externí odkaz:
https://doaj.org/article/7ff34c69a231482fa4c4bba2e9a493f3
Autor:
Miriam Rosás-Umbert, Beatriz Mothe, Marc Noguera-Julian, Rocío Bellido, Maria C Puertas, Jorge Carrillo, C Rodriguez, Núria Perez-Alvarez, Patricia Cobarsí, Carmen E Gomez, Mariano Esteban, Jose Luis Jímenez, Felipe García, Julià Blanco, Javier Martinez-Picado, Roger Paredes, Christian Brander
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0184929 (2017)
The most relevant endpoint in therapeutic HIV vaccination is the assessment of time to viral rebound or duration of sustained control of low-level viremia upon cART treatment cessation. Structured treatment interruptions (STI) are however not without
Externí odkaz:
https://doaj.org/article/1ae290b7156c43fbb11709d487b7016b
Autor:
Christian Manzardo, Cristina Miranda, Christian Brander, Miriam Rosás-Umbert, Miriam López, José Moltó, Bonaventura Clotet, Marta Ruiz-Riol, Maria C. Puertas, Marta Valle, Beatriz Mothe, Javier Martinez-Picado, José M. Miró
Publikováno v:
Journal of Antimicrobial Chemotherapy
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
ObjectivesTo develop a population pharmacokinetic model for romidepsin given as an HIV latency reversing agent (LRA) and to explore the relationship between romidepsin exposure and its in vivo effects on viral gene expression and antiviral immunity.M
Autor:
Jesper D. Gunst, Marie H. Pahus, Miriam Rosás-Umbert, I-Na Lu, Thomas Benfield, Henrik Nielsen, Isik S. Johansen, Rajesh Mohey, Lars Østergaard, Vibeke Klastrup, Maryam Khan, Mariane H. Schleimann, Rikke Olesen, Henrik Støvring, Paul W. Denton, Natalie N. Kinloch, Dennis C. Copertino, Adam R. Ward, Winiffer D. Conce Alberto, Silke D. Nielsen, Maria C. Puertas, Victor Ramos, Jacqueline D. Reeves, Christos J. Petropoulos, Javier Martinez-Picado, Zabrina L. Brumme, R. Brad Jones, Julie Fox, Martin Tolstrup, Michel C. Nussenzweig, Marina Caskey, Sarah Fidler, Ole S. Søgaard
Publikováno v:
Gunst, J D, Pahus, M H, Rosás-Umbert, M, Lu, I-N, Benfield, T, Nielsen, H, Johansen, I S, Mohey, R, Østergaard, L, Klastrup, V, Khan, M, Schleimann, M H, Olesen, R, Støvring, H, Denton, P W, Kinloch, N N, Copertino, D C, Ward, A R, Alberto, W D C, Nielsen, S D, Puertas, M C, Ramos, V, Reeves, J D, Petropoulos, C J, Martinez-Picado, J, Brumme, Z L, Jones, R B, Fox, J, Tolstrup, M, Nussenzweig, M C, Caskey, M, Fidler, S & Søgaard, O S 2022, ' Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1 : a phase 1b/2a, randomized trial ', Nature Medicine, vol. 28, no. 11, pp. 2424-2435 . https://doi.org/10.1038/s41591-022-02023-7
Gunst, J D, Pahus, M H, Rosás-Umbert, M, Lu, I-N, Benfield, T, Nielsen, H, Johansen, I S, Mohey, R, Østergaard, L, Klastrup, V, Khan, M, Schleimann, M H, Olesen, R, Støvring, H, Denton, P W, Kinloch, N N, Copertino, D C, Ward, A R, Alberto, W D C, Nielsen, S D, Puertas, M C, Ramos, V, Reeves, J D, Petropoulos, C J, Martinez-Picado, J, Brumme, Z L, Jones, R B, Fox, J, Tolstrup, M, Nussenzweig, M C, Caskey, M, Fidler, S & Søgaard, O S 2022, ' Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1 : a phase 1b/2a, randomized trial ', Nature Medicine . https://doi.org/10.1038/s41591-022-02023-7
Gunst, J D, Pahus, M H, Rosás-Umbert, M, Lu, I N, Benfield, T, Nielsen, H, Johansen, I S, Mohey, R, Østergaard, L, Klastrup, V, Khan, M, Schleimann, M H, Olesen, R, Støvring, H, Denton, P W, Kinloch, N N, Copertino, D C, Ward, A R, Alberto, W D C, Nielsen, S D, Puertas, M C, Ramos, V, Reeves, J D, Petropoulos, C J, Martinez-Picado, J, Brumme, Z L, Jones, R B, Fox, J, Tolstrup, M, Nussenzweig, M C, Caskey, M, Fidler, S & Søgaard, O S 2022, ' Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1 : a phase 1b/2a, randomized trial ', Nature Medicine, vol. 28, no. 11, pp. 2424-2435 . https://doi.org/10.1038/s41591-022-02023-7
Gunst, J D, Pahus, M H, Rosás-Umbert, M, Lu, I-N, Benfield, T, Nielsen, H, Johansen, I S, Mohey, R, Østergaard, L, Klastrup, V, Khan, M, Schleimann, M H, Olesen, R, Støvring, H, Denton, P W, Kinloch, N N, Copertino, D C, Ward, A R, Alberto, W D C, Nielsen, S D, Puertas, M C, Ramos, V, Reeves, J D, Petropoulos, C J, Martinez-Picado, J, Brumme, Z L, Jones, R B, Fox, J, Tolstrup, M, Nussenzweig, M C, Caskey, M, Fidler, S & Søgaard, O S 2022, ' Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1 : a phase 1b/2a, randomized trial ', Nature Medicine . https://doi.org/10.1038/s41591-022-02023-7
Gunst, J D, Pahus, M H, Rosás-Umbert, M, Lu, I N, Benfield, T, Nielsen, H, Johansen, I S, Mohey, R, Østergaard, L, Klastrup, V, Khan, M, Schleimann, M H, Olesen, R, Støvring, H, Denton, P W, Kinloch, N N, Copertino, D C, Ward, A R, Alberto, W D C, Nielsen, S D, Puertas, M C, Ramos, V, Reeves, J D, Petropoulos, C J, Martinez-Picado, J, Brumme, Z L, Jones, R B, Fox, J, Tolstrup, M, Nussenzweig, M C, Caskey, M, Fidler, S & Søgaard, O S 2022, ' Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1 : a phase 1b/2a, randomized trial ', Nature Medicine, vol. 28, no. 11, pp. 2424-2435 . https://doi.org/10.1038/s41591-022-02023-7
Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this phase 1b/2a, open-label, randomized controlled trial using a four-grou
Cytomegalovirus mediates expansion of IL-15–responsive innate-memory cells with SIV killing function
Autor:
Dennis J. Hartigan-O'Connor, Paul A. Luciw, Hung T. Kieu, Wenze Lu, Christian Brander, Gema Méndez-Lagares, Jaewon Lee, W. L. William Chang, Peter A. Barry, Sung Jin Kim, Lourdes Adamson, Miriam Rosás-Umbert, David E. Merriam, Ning Chin
Publikováno v:
J Clin Invest
Interindividual immune variability is driven predominantly by environmental factors, including exposure to chronic infectious agents such as cytomegalovirus (CMV). We investigated the effects of rhesus CMV (RhCMV) on composition and function of the i
Autor:
Roser Escrig, Sara Morón-López, José M. Miró, Beatriz Mothe, Christian Manzardo, Bonaventura Clotet, Michael Meulbroek, Nicola Borthwick, Hongbing Yang, Cristina Rovira, Javier Martinez-Picado, Lucy Dorrell, Pep Coll, Patricia Cobarsi, Edmund G. Wee, Miriam Rosás-Umbert, Tomáš Hanke, Christian Brander, Maria C. Puertas, Irene Ruiz, Núria Pérez-Álvarez, Alison Crook, Alvaro Sanchez-Bernabeu
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
EClinicalMedicine
EClinicalMedicine, Vol 11, Iss, Pp 65-80 (2019)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Universidad de Barcelona
EClinicalMedicine
EClinicalMedicine, Vol 11, Iss, Pp 65-80 (2019)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Background: Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1 will likely be a critical component for any effective cure strategy. Methods: BCN01 trial was a phase I, open-label, non-randomized, multicenter study in HIV-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f12e613eb092bba462459bffe71367
http://hdl.handle.net/2445/162066
http://hdl.handle.net/2445/162066
Autor:
Alex Olvera, Luis Romero-Martin, Bruna Oriol-Tordera, Miriam Rosas-Umbert, Tuixent Escribà, Beatriz Mothe, Christian Brander
Publikováno v:
Vaccines, Vol 12, Iss 3, p 279 (2024)
The efficacy of anti-viral T-cell vaccines may greatly depend on their ability to generate high-magnitude responses targeting a broad range of different epitopes. Recently, we created the HIV T-cell immunogen HTI, designed to generate T-cell response
Externí odkaz:
https://doaj.org/article/3e38dbd850c44131bf763791e9e2d017
Autor:
Lamin B. Cham, Jesper D. Gunst, Mariane H. Schleimann, Giacomo S. Frattari, Miriam Rosas-Umbert, Line K. Vibholm, Renée M. van der Sluis, Martin R. Jakobsen, Rikke Olesen, Lin Lin, Martin Tolstrup, Ole S. Søgaard
Publikováno v:
iScience, Vol 26, Iss 9, Pp 107628- (2023)
Summary: Human plasmacytoid dendritic cells (pDCs) play a central role in initiating and activating host immune responses during infection. To understand how the transcriptome of pDCs is impacted by HIV-1 infection and exogenous stimulation, we isola
Externí odkaz:
https://doaj.org/article/c71981a857e54b519eb37f5423105348